WO2000068245A1 - 14β-H-STEROLS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND USE OF THESE DERIVATIVES FOR THE PREPARATION OF MEIOSIS REGULATING MEDICAMENTS - Google Patents

14β-H-STEROLS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND USE OF THESE DERIVATIVES FOR THE PREPARATION OF MEIOSIS REGULATING MEDICAMENTS Download PDF

Info

Publication number
WO2000068245A1
WO2000068245A1 PCT/EP2000/004092 EP0004092W WO0068245A1 WO 2000068245 A1 WO2000068245 A1 WO 2000068245A1 EP 0004092 W EP0004092 W EP 0004092W WO 0068245 A1 WO0068245 A1 WO 0068245A1
Authority
WO
WIPO (PCT)
Prior art keywords
dimethyl
5αj4β
designates
diol
hydrogen atom
Prior art date
Application number
PCT/EP2000/004092
Other languages
English (en)
French (fr)
Inventor
Peter Esperling
Joachim Kuhnke
Henry Laurent
Thorsten Blume
Christa Hegele-Hartung
Monika Lessl
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2000616219A priority Critical patent/JP2002544136A/ja
Priority to IL14537300A priority patent/IL145373A0/xx
Priority to BR0010449-3A priority patent/BR0010449A/pt
Priority to PL00352029A priority patent/PL352029A1/xx
Priority to EEP200100592A priority patent/EE200100592A/xx
Priority to CA002373442A priority patent/CA2373442A1/en
Priority to AU47561/00A priority patent/AU4756100A/en
Priority to EP00929510A priority patent/EP1177205A1/en
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Priority to SK1621-2001A priority patent/SK16212001A3/sk
Priority to KR1020017014304A priority patent/KR20020013541A/ko
Priority to EA200101157A priority patent/EA200101157A1/ru
Publication of WO2000068245A1 publication Critical patent/WO2000068245A1/en
Priority to NO20015488A priority patent/NO20015488L/no
Priority to BG106093A priority patent/BG106093A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J15/00—Stereochemically pure steroids containing carbon, hydrogen, halogen or oxygen having a partially or totally inverted skeleton, e.g. retrosteroids, L-isomers

Definitions

  • the present invention relates to pharmaceutically active sterols, to pharmaceutical compositions comprising them as active substances and to the use of these novel compounds for the preparation of medicaments. More particularly it has been found that the sterols of the invention can be used for regulating meiosis.
  • Meiosis is the unique and ultimate event of germ cells on which sexual reproduction is based. Meiosis comprises two meiotic divisions. During the first division, exchange between maternal and paternal genes take place before the pairs of chromosomes are separated into the two daughter cells. These contain only half the number (1 n) of chromosomes and 2c DNA. The second meiotic division proceeds without a DNA synthesis. This division therefore results in the formation of the haploid germ cells with only 1c DNA.
  • the meiotic events are similar in the male and female germ cells, but the time schedule and the differentiation processes which lead to ova and to spermatozoa differ profoundly.
  • All female germ cells enter the prophase of the first meiotic division early in life, often before birth, but all are arrested as oocytes later in the prophase (dictyate state) until ovulation after puberty.
  • the female has a stock of oocytes which is drawn upon until the stock is exhausted.
  • Meiosis in females is not completed until after fertilization, and results in only one ovum and two abortive polar bodies per germ cell.
  • only some of the male germ cells enter meiosis from puberty and leave a stem population of germ cells throughout life.
  • meiosis in the male cell proceeds without significant delay and produces 4 spermatozoa. Only little is known about the mechanism which control the initiation of meiosis in the male and in the female. In the oocyte, new studies indicate that follicular purines, hypoxanthine or adenosine, could be responsible for meiotic arrest [Downs, S.M. et al. Dev Biol 82 (1985) 454-458: Epplg. J. J. et al Dev Biol 119 (1986) 313-321 ; and Downs, S.M. Mol Reprod Dev 35 (1993) 82-94].
  • the present invention relates to 14 ⁇ -H-sterols of the general formula
  • R 3 designates a hydrogen atom or together with R 3' an additional bond
  • R 3' designates a hydrogen atom or together with R 3 an additional bond
  • R 4 designates a hydrogen atom or a methyl group
  • R 4' designates a hydrogen atom or a methyl group
  • R 7 designates a hydrogen atom or together with R 8 an additional bond
  • R 8 designates a hydrogen atom or together with R 7 or together with R 9 an additional bond
  • R 9 designates a hydrogen atom or together with R 8 or together with R 1 an additional bond
  • R 15 designates a hydrogen atom, a hydroxy group, a halogen atom or together with R 15' an oxo group or together with R 16 an additional bond or together with R 22' an oxygen bridge
  • R 15' designates a hydrogen atom, an linear or branched alkyl group, a C 6 -C 10 aryl group or together with R 15 an oxo group
  • R 16 designates a hydrogen atom, a hydroxy group, a halogen atom or together with R 15 an additional bond or together with R 22 an additional bond
  • R 22 designates a hydrogen atom, a linear or branched optionally substituted alkyl or alkenyl group, an optionally substituted C 6 -C 10 aryl group or together with R S an additional bond or together with R 22' a linear or
  • an alkyl group - when used alone or in combinations - may be a straight or branched alkyl group.
  • the expression C.-Cg alkyl designates an alkyl group having from one to eight carbon atoms: preferred examples are methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, tert-butyl, pentyl, iso-pentyl, hexyl and cyclohexyl.
  • alkenyl group refers to an unsaturated alkyl group. Preferred examples are vinyl, allyl, isopropenyl and prenyl.
  • halogen means fluoro, chloro, bromo or iodide.
  • C 6 -C 10 aryl group designates a phenyl group, that is optionally substituted by halogen, (C C 4 )alkoxy, hydroxy or (C 1 -C 4 )alkyl groups.
  • C,-C 8 linear or branched alkylidene group stands for an alkyliden group having one to eight carbon atoms.
  • This group is connected via a double bond to carbon 22 of the steroid.
  • Preferred examples are methylene, ethylidene, propylidene, isopropylidene, butylidene, iso- butyliden, pentylidene, iso-pentylidene, neo-pentylidene and cyclohexylidene.
  • Preferred compounds of formula I are those which inhibit the germinal vesicle breakdown by at least 20 %, preferably at least 40 % , especially preferred at least 60 % when tested in an oocyte test as described in example 13 and which do not activate meiosis in an oocyte test as described in example 12.
  • the compounds of the general formula I have a number of chiral centres in the molecule and thus exist in several isomeric forms. All these isome c forms and mixtures thereof are within the scope of the invention (unless otherwise noted).
  • Preferred compounds of formula I are such with an 3 ⁇ -OH group and a ⁇ 8 double bond.
  • compounds of formula I are preferred, wherein R 15 designates a hydrogen atom or a hydroxy group.
  • R 22 designates a C.-C 8 linear or branched optionally substituted alkyl group or together with R 22' a linear or branched alkylidene group.
  • esters of compounds of the general formula I are formally derived by esterification of one or more hydroxylic groups of a compound of formula I with an acid which can for example be selected from the group of acids comprising succinic acid, glutaric acid and other aliphatic dicarboxylic acids, nicotinic acid, isonicotinic acid, ethylcarbonic acid, phosphoric acid, sulphonic acid, sulphamic acid, benzoic acid, acetic acid, propionic acid and other aliphatic monocarboxylic acids.
  • an acid which can for example be selected from the group of acids comprising succinic acid, glutaric acid and other aliphatic dicarboxylic acids, nicotinic acid, isonicotinic acid, ethylcarbonic acid, phosphoric acid, sulphonic acid, sulphamic acid, benzoic acid, acetic acid, propionic acid and other aliphatic monocarboxylic acids.
  • Especially preferred compounds of formula I of the present invention are the following:
  • the compounds of the present invention are synthesized according to the following general procedures:
  • sterols that are used as starting materials can be synthesized according to literature procedures:
  • the reactions can be carried out in the presence of different steroidal side chains (R s ) like cholesterol, ergosterol, sitosterol or stigmasterol side chain
  • the ⁇ 8J5-diene of general formula 10 can be obtained by the following sequence. Sodium borohydride reduction of ketone 4 gives 15 ⁇ -alcohol 8 as the major diastereomer. Elimination to the ⁇ 8J5-diene of general formula 9 can be carried out with Martin ' s sulfurane. Deprotection gives the desired alcohols of general formula 10 (scheme 3).
  • Derivatives which are saturated in position 15 can be obtained by the following route. 15 ⁇ -Alcohols of the general formula e can be reacted with methanesulfonic acid chlorid. Mesylate 11 can then be reduced with lithium aluminiumhydride. Compounds of general formula 12 are obtained (scheme 4). scheme 4:
  • R stero , ergosterol side chain
  • R stero i ergosterol side chain
  • Diols 20 can be eliminated to to the following sterols. Treatment with Martin ' s sulfurane gives a mono- and a bis-eliminated product. Subsequent cleavage of the benzoate can easily be achieved by reduction to give diol 23 and triene 24 respectively (scheme 7).
  • Scheme 7 :
  • Tosylate 14 can be treated with a base like lithium diisopropylamide or different grignard compounds to deprotonate the ketone at position 16.
  • compositions comprising one or more compounds of the general formula I as active substances
  • the compositions may further comprise pharmaceutically acceptable excipients well known in the art like carriers, diluents aosorption enhancers, preservatives, buffers, agents for adjusting the osmotic pressure, tablet disintegrating agents and other ingredients which are conventionally used in the art
  • solid carriers are magnesium carbonate, magnesium stearate, dextrin, lactose, sugar, talc, gelatin, pectin, tragacanth, methylcellulose, sodium carboxymethyl cellulose, low melting waxes and cacao butter
  • Liquid compositions include sterile solutions, suspensions and emulsions Such liquid compositions may be suitable for injection or for use in connection with ex vivo and in vitro fertilization
  • the liquid compositions may contain other ingredients which are conventionally used in the art, some of which are mentioned in the list above
  • a composition for transdermal administration of a compound of this invention may be provided in the form of a patch and a composition for nasal administraton may be provided in the form of a nasal spray in liquid or powder form
  • compositions of the invention are prepared by intimately bringing into association the active compound with the liquid or solid auxiliary ingredients and then, if necessary, shaping the product into the desired formulation
  • not more than 1000 mg, preferably not more than 100 mg, and in some preferred instances not more than 10 mg of a compound of formula I is to be administered to mammals, e g to humans, per day
  • the present invention relates to the use of the compounds of the general formula I for the preparation of a meiosis-regulating medicament
  • the compounds of the present invention influence the meiosis in oocytes as well as in male germ cells
  • the compounds of the general formula I are promising as new fertility-regulating agents without the usual side effects on the somatic cells which are known from the hitherto used hormonal contraceptives which are based on estrogens and/or gestagens
  • Contraception in females can be achieved by administration of a compound of the invention which inhibits the meiosis, so that no mature oocytes are produced
  • contraception in males can be achieved by administration of a compound of the invention which inhibits the meiosis, so that no mature sperm cells are produced
  • the present invention relates to a method of regulating meiosis comprising administering to a subject in need of such a regulation an effective amount of one or more compounds of the general formula I.
  • compositions containing a compound of the invention may be any route which effectively transports the active compound to its site of action.
  • compositions which comprises at least one compound of the invention in connection with a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier for oral use, such compositions are preferably in the form of capsules or tablets.
  • the compounds of the invention When used as a contraceptive, the compounds of the invention will either have to be administered continuously or cyclically.
  • the present invention relates to the use of a 14 ⁇ -hydrogen group in a sterol compound to increase the inhibitory activity of a meiosis inhibiting substance.
  • LiAIH 4 LiAIH 4 were added to a stirred solution of 300 mg 3 ⁇ -benzoyloxy-4,4- d ⁇ methyl-5 ⁇ J4 ⁇ -ergosta-8,22-d ⁇ en-15-one in 30 ml diethylether and the mixture was stirred for 30 minutes at room temperature. Then 1 ml of saturated ammonium chloride solution was added After 10 minutes the solution was filtered and the solvent removed in vacuo The residue was separated by chromatography to give 100 mg 4,4-d ⁇ methyl-5 ⁇ J4 ⁇ -ergosta-8,22-d ⁇ ene-3 ⁇ J5 ⁇ - diol.
  • Example 4 4,4-dimethyl-24-nor-5 ⁇ ,14 ⁇ -cholesta-8,15-dien-3 ⁇ -ol a) (20S)-3 ⁇ -benzoyloxy-20-hydroxymethyl-4,4-d ⁇ methyl-5 ⁇ , 14 ⁇ -pregn-8-en-15- one and (20S)-3 ⁇ -benzoyloxy-20-hydroxymethyl-4,4-d ⁇ methyl-5 ⁇ , 14 ⁇ -pregn-8-
  • the crude product was purified by column chromatography to give 40 mg (20R)- 4,4,20Jr ⁇ methyl-16 ⁇ ,21 -cyclo-5 ⁇ J4 ⁇ -pregn-8-ene-3 ⁇ J5 ⁇ -d ⁇ ol and 30 mg (20R)- 4,4,20-tnmethyl-16 ⁇ ,21-cyclo-5 ⁇ J4 ⁇ -pregn-8-ene-3 ⁇ J 5 ⁇ -d ⁇ ol as white solids
  • Example 12 Testing of meiosis-activating substances in the oocyte test
  • Oocytes were obtained from immature female mice (C57BI/6J x DBA/2J F1- hybrids, Bomholtgaard, Denmark) weighing 13 - 16 grams, that were kept under controlled lighting and temperature.
  • the mice received an intra-peritoneal injection of 0.2 ml gonadotropins (Gonal F, Serono, Solna, Sweden , containing 20 IU FSH, alternatively, Puregon, Organon, Swords, Ireland containing 20 IU FSH) and 48 hours later the animals were killed by cervical dislocation.
  • the ovaries were dissected out and the oocytes were isolated in Hx-medium (see below) under a stereo microscope by manual rupture of the follicles using a pair of 27 gauge needles.
  • Spherical, naked oocytes (NO) displaying an intact germinal vesicle (GV) were placed in ⁇ -minimum essential medium ( ⁇ -MEM without ribonucleosides, Gibco BRL, Cat.No. 22561 ) supplemented with 3 mM hypoxanthine (Sigma Cat. No. H-9377), 8 mg/ml Human Serum Albumin (HSA, State Serum Institute, Denmark), 0,23 mM pyrubate (Sigma, Cat. No.
  • Hx-medium 2 mM glutamine (Flow Cat. No. 16-801 ), 100 lU/ml penicillin and 100 ⁇ g/ml streptomycin (Flow, Cat No. 16-700).
  • This medium was designated Hx-medium.
  • the oocytes were rinsed three times in Hx-medium and cultured in 4-well multidishes (Nuncion, Denmark) in which each well contained 0.4 ml of Hx- medium and 35 - 45 oocytes.
  • One control i.e. 35 - 45 oocytes cultured in Hx- medium with no addition of test compound was always run simultaneously with the test cultures, which were made with different concentrations of the compounds to be tested.
  • the cultures were performed at 37 °C and 100 % humidity with 5 % CO 2 in air.
  • the culture time was 22 - 24 hours.
  • the number of oocytes with germinal vesicle (GV) or germinal vesicle breakdown (GVB) and those with polar body (PB) was counted using a stereo microscope or an inverted microscope with differential interference contrast equipment.
  • the percentage of oocytes with GVB per total number of oocytes and the percentage of oocytes with PB per total number of oocytes was calculated in the test cultures and compared to the control culture.
  • Example 13 Test of meiosis-inhibiting substances in the oocyte test
  • Germinal vesicle (GV) oocytes were obtained from immature FSH treated female mice using the same methods as described in Example 1 (see above). Naked oocytes (NO) were rinsed three times in Hx-medium. 4,4-Dimethylcholest-B, 14,24-trien-3 ⁇ -ol (FF-MAS) has previously been shown to induce meiosis in NO invitro (Byskov, A.G. et al. Nature 374 (1995) 559 - 562).
  • oocytes with germinal vesicle (GV) or germinal vesicle breakdown (GVB) and those with polar body (PB) was counted using a stereo microscope or an inverted microscope with differential interference contrast equipment.
  • the percentage of oocytes with GVB + PB per total number of oocytes were calculated in the test cultures and in the control (positive and negative) culture groups.
  • the relative inhibition of the test compound was calculated by the following formula:
  • Oocytes arrested in meiosis are characterised by an intact nucleus with a prominent nucleolus, known as germinal vesicle (GV).
  • GV germinal vesicle
  • PB polar body
  • GV germinal vesicle
  • GVB germinal vesicle breakdown
  • PB polar bodies
  • n number of

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/EP2000/004092 1999-05-10 2000-05-05 14β-H-STEROLS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND USE OF THESE DERIVATIVES FOR THE PREPARATION OF MEIOSIS REGULATING MEDICAMENTS WO2000068245A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AU47561/00A AU4756100A (en) 1999-05-10 2000-05-05 14beta-h-sterols, pharmaceutical compositions comprising them and use of these derivatives for the preparation of meiosis regulating medicaments
BR0010449-3A BR0010449A (pt) 1999-05-10 2000-05-05 14beta-h-esteróis, composições farmacêuticas que compreendem os mesmos e uso destes derivados para a preparação de medicamentos reguladores da meiose
PL00352029A PL352029A1 (en) 1999-05-10 2000-05-05 14-beta-h-sterols, pharmaceutical compositions containing these sterols and use of these derivatives for obtaining drugs to regulate meioses
EEP200100592A EE200100592A (et) 1999-05-10 2000-05-05 14ß-H-steroolid, neid sisaldavad farmatseutilisedkompositsioonid ja nende derivaatide kasutamine meioosi reguleerivate ravimite valmistamiseks
CA002373442A CA2373442A1 (en) 1999-05-10 2000-05-05 14.beta.-h-sterols, pharmaceutical compositions comprising them and use of these derivatives for the preparation of meiosis regulating medicaments
JP2000616219A JP2002544136A (ja) 1999-05-10 2000-05-05 １４β−Ｈ−ステロール類、それらを含んで成る医薬組成物、及び減数分裂調節医薬の調節のためのそれらの誘導体の使用
EP00929510A EP1177205A1 (en) 1999-05-10 2000-05-05 14$g(b)-H-STEROLS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND USE OF THESE DERIVATIVES FOR THE PREPARATION OF MEIOSIS REGULATING MEDICAMENTS
IL14537300A IL145373A0 (en) 1999-05-10 2000-05-05 14b-h-sterols, pharmaceutical compositions comprising them and use of these derivatives for the preparation of meiosis regulating medicaments
SK1621-2001A SK16212001A3 (sk) 1999-05-10 2000-05-05 14beta-H-steroly, ich použitie ako liečiv a farmaceutické prostriedky, ktoré ich obsahujú
KR1020017014304A KR20020013541A (ko) 1999-05-10 2000-05-05 14β-Ｈ-스테롤, 그를 포함하는 제약 조성물, 및 감수분열조절 약제 제조에 있어서 그의 유도체의 용도
EA200101157A EA200101157A1 (ru) 1999-05-10 2000-05-05 14β-H-СТЕРОЛЫ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ЭТИХ ПРОИЗВОДНЫХ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ, РЕГУЛИРУЮЩИХ МЕЙОЗ
NO20015488A NO20015488L (no) 1999-05-10 2001-11-09 14<beta>-H-steroler, farmasöytiske preparater som omfatter dem, og anvendelse av disse derivatene til fremstilling avmeioseregulerende medikamenter
BG106093A BG106093A (en) 1999-05-10 2001-11-09 14beta-h-sterols, pharmaceutical compositions comprising them and the use of these derivatives for the preparation of meiosis regulating medicaments

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99250153 1999-05-10
EP99250153.6 1999-05-10

Publications (1)

Publication Number Publication Date
WO2000068245A1 true WO2000068245A1 (en) 2000-11-16

Family

ID=8241145

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/004092 WO2000068245A1 (en) 1999-05-10 2000-05-05 14β-H-STEROLS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND USE OF THESE DERIVATIVES FOR THE PREPARATION OF MEIOSIS REGULATING MEDICAMENTS

Country Status (18)

Country Link
EP (1) EP1177205A1 (ko)
JP (1) JP2002544136A (ko)
KR (1) KR20020013541A (ko)
CN (1) CN1350543A (ko)
AU (1) AU4756100A (ko)
BG (1) BG106093A (ko)
BR (1) BR0010449A (ko)
CA (1) CA2373442A1 (ko)
CZ (1) CZ20013981A3 (ko)
EA (1) EA200101157A1 (ko)
EE (1) EE200100592A (ko)
HU (1) HUP0201098A2 (ko)
IL (1) IL145373A0 (ko)
NO (1) NO20015488L (ko)
PL (1) PL352029A1 (ko)
SK (1) SK16212001A3 (ko)
WO (1) WO2000068245A1 (ko)
ZA (1) ZA200110073B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012044817A2 (en) * 2010-10-01 2012-04-05 Indiana University Research And Technology Corporation Process for preparing delta-7,9(11) steroids from ganoderma lucidum and analogs thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112334476B (zh) * 2019-09-09 2022-03-15 邦泰生物工程(深圳)有限公司 一种合成鹅去氧胆酸的方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4202891A (en) * 1977-05-16 1980-05-13 Kandutsch Andrew A 15-Oxygenated sterol compounds and the use of such compounds to inhibit the biosynthesis of sterols
WO1996027658A1 (en) * 1995-03-06 1996-09-12 Novo Nordisk A/S Stimulation of meiosis
WO1999058549A1 (en) * 1998-05-13 1999-11-18 Novo Nordisk A/S Meiosis regulating compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4202891A (en) * 1977-05-16 1980-05-13 Kandutsch Andrew A 15-Oxygenated sterol compounds and the use of such compounds to inhibit the biosynthesis of sterols
WO1996027658A1 (en) * 1995-03-06 1996-09-12 Novo Nordisk A/S Stimulation of meiosis
WO1999058549A1 (en) * 1998-05-13 1999-11-18 Novo Nordisk A/S Meiosis regulating compounds

Non-Patent Citations (25)

* Cited by examiner, † Cited by third party
Title
AKIHISA, TOSHIHIRO ET AL: "4.alpha.-Methyl-5.alpha.,14.beta.-ergosta-8,24(241)-dien-3.beta.-ol ("triticusterol"): the first naturally occurring 14.beta.(H)-steroid", J. CHEM. SOC., PERKIN TRANS. 1 (4), 497-500, 21 February 1999 (1999-02-21), XP002147502 *
ALLEVI, PIETRO ET AL: "Hydroboration of 5.alpha.-ergost-8-en-3.beta.-ol", STEROIDS (1989), 54(2), 133-43, XP002147499 *
ANASTASIA, M. ET AL: "Stereochemical course of the hydroboration of highly hindered steroidal olefins. A ready synthesis of 14.beta.- and 8.alpha.,14.beta.-steroids", STEROIDS (1986), 47(2-3), 131-41, XP002147500 *
ANASTASIA, MARIO ET AL: "A ready synthesis of 5.alpha.,14.beta.-cholest-7-en-3.beta.-ol", J. CHEM. SOC., PERKIN TRANS. 1 (1976), (4), 378-80, XP002147498 *
ARINGER, LEIF ET AL: "Chromatographic properties and mass spectrometric fragmentation of dioxygenated C27-, C28-, and C29-steroids", BIOMED. MASS SPECTROM. (1981), 8(5), 183-203, XP000955687 *
BENTLEY, T. J. ET AL: "Synthesis and configuration of 32-norlanosterol derivatives", J. CHEM. SOC., PERKIN TRANS. 1 (1972), (5), 749-54, XP002147503 *
BIOCHEM. INT. (1987), 15(2), 403-8 *
BIOCHEM. PHARMACOL. (1979), 28(2), 249-52 *
CHEM. PHYS. LIPIDS (1988), 46(4), 245-51 *
CHEMICAL ABSTRACTS, vol. 107, no. 25, 21 December 1987, Columbus, Ohio, US; abstract no. 228799, SCHROEPFER, GEORGE J., JR. ET AL: "15.beta.-Methyl-5.alpha.,14.beta.-cholest-7-ene-3.beta.,15.alpha.- diol. Synthesis, structure, and inhibition of sterol synthesis in animal cells" XP002147506 *
CHEMICAL ABSTRACTS, vol. 108, no. 25, 20 June 1988, Columbus, Ohio, US; abstract no. 221960, BOWEN, SAMUEL T. ET AL: "Inhibitors of sterol synthesis. Concerning the structure of 15.beta.-methyl-5.alpha.,14.beta.-cholest-7-ene-3.beta.,15.alpha.- diol, an inhibitor of cholesterol biosynthesis" XP002147505 *
CHEMICAL ABSTRACTS, vol. 115, no. 19, 11 November 1991, Columbus, Ohio, US; abstract no. 197716, WILSON, WILLIAM K. ET AL: "Inhibitors of sterol synthesis. Characterization of.beta.,.gamma.-unsaturated analogs of 3.beta.-hydroxy-5.alpha.- cholest-8(14)-en-15-one and their effects on 3-hydroxy-3- methylglutaryl coenzyme A reductase activity in CHO-K1 cells" XP002147504 *
CHEMICAL ABSTRACTS, vol. 51, no. 20, 25 October 1957, Columbus, Ohio, US; abstract no. 15425h, J. B. BREAM ET AL: "Steric requirements for H-catalyst induced migration of the olefinic bond" XP002147510 *
CHEMICAL ABSTRACTS, vol. 86, no. 17, 25 April 1977, Columbus, Ohio, US; abstract no. 116158, GALLI KIENLE, MARZIA ET AL: "Inversion of the unnatural cis C/D sterol ring junction of 5.alpha., 14.beta.-cholest-7-en-3.beta.-ol by rat-liver enzymes" XP002147509 *
CHEMICAL ABSTRACTS, vol. 88, no. 3, 16 January 1978, Columbus, Ohio, US; abstract no. 16656, SCHROEPFER, GEORGE J., JR. ET AL: "Inhibition of sterol biosynthesis in L cells and mouse liver cells by 15-oxygenated sterols" XP002147508 *
CHEMICAL ABSTRACTS, vol. 91, no. 3, 16 July 1979, Columbus, Ohio, US; abstract no. 14571, SCHROEPFER, GEORGE J., JR. ET AL: "Inhibition of sterol synthesis in animal cells by 15-oxygenated sterols with the unnatural cis-C-D ring junction - 5.alpha.,14.beta.-cholest-7-en-15.alpha.-ol-3-one and 5.alpha.,14.beta.-cholest-7-en-15.beta.-ol-3-one" XP002147507 *
EUR. J. BIOCHEM. (1977), 73(1), 1-6 *
J. BIOL. CHEM. (1977), 252(24), 8975 *
J. LIPID RES. (1991), 32(7), 1215-27 *
JOURNAL OF THE CHEMICAL SOCIETY, 1957, LETCHWORTH GB, pages 1974 - 1981 *
MILLER, LARRY R. ET AL: "Inhibitors of sterol synthesis. Studies of in vitro effects of C27 15-oxygenated sterols on sterol synthesis in cell-free homogenates of rat liver", J. BIOL. CHEM. (1982), 257(5), 2412-19, XP002147495 *
PASCAL, ROBERT A., JR. ET AL: "15-Oxygenated sterols with the unnatural cis-C-D ring junction. Studies of the metabolism of 5.alpha.,14.beta.-cholest-7-ene- 3.beta.,15.alpha.-diol and 5.alpha.,14.beta.-cholest-7-ene- 3.beta.,15.beta.-diol", J. BIOL. CHEM. (1980), 255(8), 3565-70, XP002147496 *
SCHROEPFER, GEORGE J., JR. ET AL: "Further studies on the inhibition of sterol biosynthesis in animal cells by 15-oxygenated sterols", CHEM. PHYS. LIPIDS (1979), 25(3), 265-85, XP000949295 *
SIDDIQUI, ABDUL U. ET AL: "Inhibitors of sterol synthesis. Synthesis and spectral properties of 3.beta.-hydroxy-5.alpha.-cholestan-15-one and its 14.beta.-epimer and their effects on 3-hydroxy-3-methylglutaryl coenzyme A reductase activity", CHEM. PHYS. LIPIDS (1994), 74(1), 1-15, XP000949296 *
SIDDIQUI, ABDUL U. ET AL: "Inhibitors of sterol synthesis: effects of a 7.alpha.-alkyl analog of 3.beta.-hydroxy-5.alpha.-cholest-8(14)-en-15-one on 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured mammalian cells and on serum cholesterol levels and other parameters in rats", CHEM. PHYS. LIPIDS (1994), 70(2), 163-78, XP000949297 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012044817A2 (en) * 2010-10-01 2012-04-05 Indiana University Research And Technology Corporation Process for preparing delta-7,9(11) steroids from ganoderma lucidum and analogs thereof
WO2012044817A3 (en) * 2010-10-01 2012-06-14 Indiana University Research And Technology Corporation Process for preparing delta-7,9(11) steroids from ganoderma lucidum and analogs thereof
US20130184244A1 (en) * 2010-10-01 2013-07-18 Indiana University Research And Technology Corporation Process for preparing delta-7,9(11) steroids from ganoderma lucidum and analogs thereof
US9376462B2 (en) * 2010-10-01 2016-06-28 Indiana University Research And Technology Corporation Process for preparing delta-7,9(11) steroids from Ganoderma lucidum and analogs thereof

Also Published As

Publication number Publication date
BG106093A (en) 2002-05-31
NO20015488D0 (no) 2001-11-09
CN1350543A (zh) 2002-05-22
CA2373442A1 (en) 2000-11-16
PL352029A1 (en) 2003-07-28
JP2002544136A (ja) 2002-12-24
KR20020013541A (ko) 2002-02-20
NO20015488L (no) 2002-01-09
IL145373A0 (en) 2002-06-30
EA200101157A1 (ru) 2002-06-27
HUP0201098A2 (en) 2002-08-28
ZA200110073B (en) 2003-03-06
AU4756100A (en) 2000-11-21
EE200100592A (et) 2003-02-17
BR0010449A (pt) 2002-02-13
SK16212001A3 (sk) 2002-02-05
EP1177205A1 (en) 2002-02-06
CZ20013981A3 (cs) 2002-02-13

Similar Documents

Publication Publication Date Title
US6884796B2 (en) Meiosis regulating compounds
RU2182909C2 (ru) Стероиды, способ регулирования мейоза
EP0946584B1 (en) Meiosis regulating compounds
US6177420B1 (en) 20-aralkyl-5α-pregnane derivatives
EP1077992B1 (en) Use of meiosis regulating compounds
WO2000068245A1 (en) 14β-H-STEROLS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND USE OF THESE DERIVATIVES FOR THE PREPARATION OF MEIOSIS REGULATING MEDICAMENTS
MXPA01009970A (en) 14&amp;bgr;-H-STEROLS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND USE OF THESE DERIVATIVES FOR THE PREPARATION OF MEIOSIS REGULATING MEDICAMENTS
EP1245572A1 (en) Aminosterol compounds, their use in the preparation of meiosis-regulating medicaments and method for their preparation
EP1127890A1 (en) Steroid derivatives with an additional ring annulated to ring A and use of these derivatives for the preparation of meiosis regulating medicaments
WO2000047604A1 (en) Unsaturated cholestane derivatives and their use for the preparation of meiosis regulating medicaments
MXPA99005771A (en) Meiosis regulating compounds
EP1137660A1 (en) 22s-hydroxycholesta-8,14-diene derivatives with meiosis regulating activity
CZ404799A3 (cs) Deriváty 20-araIkyl-5alfa-pregnanu
CA2528904A1 (en) Thiomorpholino steroid compounds, the use thereof for the preparation of meiosis-regulating medicaments and method for the preparation thereof
MXPA01007526A (en) Unsaturated cholestane derivatives and their use for the preparation of meiosis regulating medicaments

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-801/01

Country of ref document: YU

Ref document number: 00807346.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2000929510

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/009970

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/01250/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 515113

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PV2001-3981

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2000 616219

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2373442

Country of ref document: CA

Ref document number: 2373442

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 47561/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 16212001

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2000 106093

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017014304

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200101157

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2001/10073

Country of ref document: ZA

Ref document number: 200110073

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: P20010917A

Country of ref document: HR

WWP Wipo information: published in national office

Ref document number: 2000929510

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2001-3981

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020017014304

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09959870

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000929510

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2001-3981

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1020017014304

Country of ref document: KR